Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant

Rhea-AI Filing Summary

Trevi Therapeutics director Edward T. Mathers received a new stock option grant covering 35,000 shares of common stock. The nonstatutory option has an exercise price of $13.45 per share and expires on June 2, 2036.

According to the terms, the option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as Mathers continues to serve as a director, employee, or consultant of Trevi Therapeutics.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mathers Edward T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Nonstatutory Stock Option (right to buy)	35,000	$0.00	--

Holdings After Transaction: Nonstatutory Stock Option (right to buy) — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 options Exercise price: $13.45 per share Expiration date: June 2, 2036 +3 more

6 metrics

Option grant size 35,000 options Nonstatutory stock option covering 35,000 shares

Exercise price $13.45 per share Conversion or exercise price of the option

Expiration date June 2, 2036 Option expiration for the nonstatutory stock option

Underlying shares 35,000 shares Underlying Trevi common stock linked to the option

Grant date June 3, 2026 Date on which the option was granted

Post-transaction derivative holdings 35,000 options Total options held following this reported transaction

Key Terms

Nonstatutory Stock Option, exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Nonstatutory Stock Option financial

"Nonstatutory Stock Option (right to buy)"

A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.

exercise price financial

"conversion_or_exercise_price": "13.4500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders of the Issuer"

continued service financial

"subject to the recipient's continued service as a director, employee or consultant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathers Edward T

(Last) (First) (Middle)

104 5TH AVE

19TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nonstatutory Stock Option (right to buy)	$13.45	06/03/2026		A		35,000		(1)	06/02/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

	/s/ Zachary Bambach, attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Trevi Therapeutics (TRVI) report for Edward T. Mathers?

Trevi Therapeutics reported a stock option grant to director Edward T. Mathers. He received a nonstatutory option for 35,000 shares of common stock, structured as compensation, rather than an open-market purchase or sale of existing shares.

What are the key terms of Edward T. Mathers’ new Trevi Therapeutics (TRVI) stock option?

The option covers 35,000 shares at an exercise price of $13.45. It is a nonstatutory stock option that expires on June 2, 2036, giving Mathers the right to buy Trevi common shares at that fixed price if vested.

When do Edward T. Mathers’ Trevi Therapeutics (TRVI) options vest?

The option is scheduled to fully vest based on time and service conditions. Vesting occurs on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting held after that date, subject to continued service.

Is the Trevi Therapeutics (TRVI) Form 4 for an insider buy or sale of shares?

The Form 4 reflects an acquisition of stock options as compensation, not a share sale. The transaction code is “A” for a grant or award, and no open-market buying or selling of common stock is reported in this filing.

How many Trevi Therapeutics (TRVI) derivative securities does Edward T. Mathers hold after this transaction?

Following this transaction, Mathers holds 35,000 stock options as reported. These options relate to an equal number of underlying Trevi common shares and represent his derivative position from this specific grant disclosed in the Form 4.

What service requirement is tied to Edward T. Mathers’ Trevi Therapeutics (TRVI) option vesting?

Vesting depends on Mathers’ continued service with Trevi Therapeutics. He must remain a director, employee, or consultant through the vesting date, which is the earlier of one year from grant or the next annual stockholder meeting after grant.